Artrya, an Australian medical technology firm, signed a deal with The Cardiac Centre New South Wales for its Salix Coronary Anatomy software to enhance cardiovascular disease diagnosis by detecting vulnerable plaque.

The software will operate across four locations, serving over 25,000 patients yearly.

Artrya anticipates its first revenues in the fourth quarter of FY24, transitioning from testing to full commercial operations.

The collaboration integrates Salix into The Cardiac Centre NSW's medical systems, aiming to revolutionise coronary artery disease care with rapid, precise diagnostics, cutting healthcare costs.